Physician profile
Robyn C Morrison
NPI 1093269623
$4,125.93
in general payments reported to CMS, 2019-2025
39 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $930 · 2022: $453 · 2023: $814 · 2024: $797 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $766.61 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $536.50 | 2022-2025 | |
| Lilly USA, LLC | $450.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $399.58 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $372.83 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $212.24 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $155.97 | 2021-2023 | Verquvo, Belsomra, Januvia |
| Sanofi-Aventis U.S. LLC | $148.81 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.67 | 2023-2025 | |
| Amgen INC. | $97.85 | 2021-2025 | Evenity, Prolia, Prolia |
| Lundbeck LLC | $89.12 | 2023-2025 | Rexulti |
| Corium, LLC | $81.02 | 2023-2024 | Azstarys |
| Exact Sciences Corporation | $58.11 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $49.82 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $42.18 | 2024-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $41.95 | 2025 | Yupelri |
| Pfizer INC. | $35.46 | 2021 | |
| Collegium Pharmaceutical, INC. | $35.00 | 2021 | |
| Vanda Pharmaceuticals INC. | $34.55 | 2024-2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.30 | 2021 | |
| Neurelis, INC. | $34.20 | 2022-2024 | Valtoco |
| Biogen, INC. | $32.09 | 2021 | |
| Eisai INC. | $30.44 | 2021 | |
| Mylan Specialty L.P. | $22.23 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $21.09 | 2025 | Auvelity |
| Corcept Therapeutics | $20.53 | 2025 | Korlym |
| Ucb, INC. | $19.87 | 2025 | Briviact |
| Sonex Health, INC. | $19.37 | 2025 | Sx-One Microknife |
| Abiomed | $18.74 | 2024 | Impella |
| Dexcom, INC. | $18.28 | 2025 | Dexcom G6 Transmitter |
| Organon LLC | $14.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.91 | 2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $13.77 | 2021 | |
| Abbott Laboratories | $13.56 | 2021 | |
| Celgene Corporation | $12.98 | 2023 | Zeposia |
| Horizon Therapeutics Plc | $12.97 | 2021 | |
| Optinose US, INC. | $12.89 | 2021 | |
| Adlon Therapeutics L.P. | $12.77 | 2021 | |
| Philips North America LLC | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.